Anti-cancer Drug (SinaDoxosome)

Introduction

This product is SinaDoxosome containing liposomal hydrochloride doxorubicin. Its formulation is in a way that inserts doxorubicin into the nanoliposome carriers and increases permeability and retention of the drug in the tumor tissue. This lipid carrier decreases the side effects of doxorubicin due to the small amount of leakage. In this way cardiac toxicity of the drug that is the most dangerous side effect is significantly reduced. SinaDoxosome is used in the treatment of various cancers and because of the high efficiency of its liposomal nature, it has significant effect on metastatic cancers including metastatic breast, ovarian cancers as well as multiple myeloma and AIDS-related Kaposi’s sarcoma.

Application

• Mainly for destroying cancer cells, reducing size and postponing tumor growth in diseases including metastatic breast cancer, advanced ovarian cancer, Multiple myeloma, and AIDS-related Kaposi’s sarcoma.

Advantage of Using Nanotechnology

Nanoliposomes are the most widely used drug delivery vehicles which increase the drug permeability and retention in the tumor tissue. In addition, use of nanoliposomes as drug carriers reduces the side effects of doxorubicin such as cardiac toxicity.

Certificates and Standards

• NanoScale Certification
• Iran Ministry of Health Certification